PI-1840/ supplier with competitive price in stock-Rechems

Details:

PI-1840 is a potent and selective inhibitor for chymotrypsin-like (CT-L) (IC50 value = 27 ± 0.14 nM) over trypsin-like and peptidylglutamyl peptide hydrolyzing (IC50 values >100 μM) activities of the proteasome.IC50 value: 27 nM(CT-L activities of the proteasome) Target: CT-L inhibitor in vitro: PI-1840 is over 100-fold more selective for the constitutive proteasome over the immunoproteasome.Mass spectrometry and dialysis studies demonstrate that PI-1840 is a noncovalent and rapidly reversible CT-L inhibitor.In intact cancer cells, PI-1840 inhibits CT-L activity, induces the accumulation of proteasome substrates p27, Bax, and IκB-α, inhibits survival pathways and viability, and induces apoptosis.Furthermore, PI-1840 sensitizes human cancer cells to the mdm2/p53 disruptor, nutlin, and to the pan-Bcl-2 antagonist BH3-M6 .in vivo: PI-1840 but not bortezomib suppresses the growth in nude mice of human breast tumor xenografts .
Shanghai Rechem science Co., Ltd.
Rechemsis focus on R&D of new APIS, signal transduction inhibitors and pharmaceutical intermediates. We follow closely the industry trend, and the latest research achievements in life science area.
Rechems is located in the largest biomedical base in China--Shanghai and cooperatively established modern production base and laboratory in surrounding areas. We have built up a good relationship with many US / European / Japanese pharmaceutical companies to conduct chemical research and inventory trading in medicinal chemistry.
Rechems's mission is to serve pharmaceutical community by providing excellent services and high-quality products in a timely manner.
Rechems's vision is to be recognized by our clients as one of the best suppliers of chemical products for our superior quality, efficient and cost-effective services.
We insist the principle of "Quality first, customer foremost, best credit, be pioneering and creative", looking forward to establishing good business relationships with customers all over the world. Let's work together for bright future!